Login to Your Account



Royalty Rates: Center Stage In Biopharma Dealmaking


Thursday, November 15, 2012
One-by-one, big pharmaceutical firms are plunging off patent cliffs. They're scrambling to fill pipelines and reinforce bottom lines. The door is open wider than ever for biotechnology companies and their coffers of innovative therapeutic candidates to negotiate lucrative licensing deals with a focus on royalty rates.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription